Related Experiment Video

Updated: Jul 9, 2025

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

9.5K

Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening

Zhen Tian1, Stacia Octaviani1, Jian Huang1,2,3

  • 1Coriell Institute for Medical Research, Camden, NJ, USA.

Expert Opinion on Therapeutic Targets
|December 9, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Acute Myeloid LeukemiaCRISPR screenIn vitro and In vivo screenSingle cell screenTherapeutic targets

More Related Videos

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

154
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.6K

Related Experiment Videos

Last Updated: Jul 9, 2025

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

9.5K
Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

154
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.6K

Related Concept Videos

CRISPR01:59

CRISPR

51.6K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
51.6K

Articles linked to this work by shared authors, journal, and citation graph.

Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism.

Molecular biology reports·2011

Evolution of activation patterns during long-duration ventricular fibrillation in pigs.

American journal of physiology. Heart and circulatory physiology·2011

A new feruloyl amide derivative from the fruits of Tribulus terrestris.

Natural product research·2011

High-amylose rice improves indices of animal health in normal and diabetic rats.

Plant biotechnology journal·2011

The cross-validated AUC for MCP-logistic regression with high-dimensional data.

Statistical methods in medical research·2011

All-optical virtual private network and ONUs communication in optical OFDM-based PON system.

Optics express·2011

Overcoming adaptive resistance to cancer immunotherapy: molecular targeting strategies for the tumor microenvironment.

Expert opinion on therapeutic targets·2026

Targeting protein misfolding and aggregation in neurodegenerative diseases: challenges for the identification and validation of targets for small molecules.

Expert opinion on therapeutic targets·2026

New and emerging therapeutics and molecular targets for attention-deficit hyperactivity disorder.

Expert opinion on therapeutic targets·2026

VAV1 targeting for cancer therapeutics: mechanistic understanding and preclinical promise.

Expert opinion on therapeutic targets·2026

Targeting the LOX-1 scavenger receptor for therapeutics and diagnostics.

Expert opinion on therapeutic targets·2026

Sirtuin signaling as therapeutic targets of immunosenescence.

Expert opinion on therapeutic targets·2026

A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.

Immunity, inflammation and disease·2026

Advances in non-invasive monitoring of drug delivery for neurodegenerative disorders.

Expert review of medical devices·2026

[Retracted] (‑)‑Epicatechin protects against myocardial ischemia‑induced cardiac injury via activation of the PTEN/PI3K/AKT pathway.

Molecular medicine reports·2026

Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.

Neuro-oncology advances·2026

Advancing Membrane Technologies for Cancer Therapy and Environmental Health: Biomimetic Innovations, Smart Technologies, and Sustainable Translation.

ACS omega·2026

Rare Diseases as Engines of Biomedical Innovation: Lessons for Gene Therapy and Common Disease.

The Yale journal of biology and medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us